TY - JOUR
T1 - Acceptance of medications for opioid use disorder in recovery housing programs in Missouri
AU - Wood, Claire A.
AU - Duello, Alex
AU - Miles, Jennifer
AU - Lohmann, Brenna
AU - Gochez-Kerr, Tatiana
AU - Richardson, Kori
AU - Anderson-Harper, Rosie
AU - Winograd, Rachel
PY - 2022/7
Y1 - 2022/7
N2 - Background Recovery housing plays an important role in supporting individuals in their recovery by building recovery capital and providing stable living environments; however, the extent to which medications for opioid use disorder (MOUD), the gold standard for OUD treatment, are accepted in recovery housing settings is unclear. The purpose of this study, as part of a larger statewide evaluation of Missouri recovery homes, was to identify the extent to which Missouri recovery houses were accepting of methadone, buprenorphine , and naltrexone as well as the extent to which the acceptance of each medication was linked to whether the recovery home encouraged tapering off MOUDs. Methods Sixty-four recovery housing managers and/or staff, out of 66 eligible recovery homes in Missouri completed the survey. Results Results indicated that methadone was the least accepted medication for long-term use followed by buprenorphine and then naltrexone. Recovery houses that had significantly lower overall acceptance of methadone encouraged tapering; however, the overall acceptance for buprenorphine and naltrexone was not significantly related to the encouragement of tapering off MOUDs. Conclusion This work highlights the need to develop reliable instruments to measure and assess MOUD-capable recovery homes and to increase knowledge and acceptance of MOUD within recovery home settings.
AB - Background Recovery housing plays an important role in supporting individuals in their recovery by building recovery capital and providing stable living environments; however, the extent to which medications for opioid use disorder (MOUD), the gold standard for OUD treatment, are accepted in recovery housing settings is unclear. The purpose of this study, as part of a larger statewide evaluation of Missouri recovery homes, was to identify the extent to which Missouri recovery houses were accepting of methadone, buprenorphine , and naltrexone as well as the extent to which the acceptance of each medication was linked to whether the recovery home encouraged tapering off MOUDs. Methods Sixty-four recovery housing managers and/or staff, out of 66 eligible recovery homes in Missouri completed the survey. Results Results indicated that methadone was the least accepted medication for long-term use followed by buprenorphine and then naltrexone. Recovery houses that had significantly lower overall acceptance of methadone encouraged tapering; however, the overall acceptance for buprenorphine and naltrexone was not significantly related to the encouragement of tapering off MOUDs. Conclusion This work highlights the need to develop reliable instruments to measure and assess MOUD-capable recovery homes and to increase knowledge and acceptance of MOUD within recovery home settings.
KW - MAT
KW - Medications for opioid use disorder
KW - Opioid use disorder
KW - Recovery
KW - Recovery housing
KW - Sober housing
UR - https://doi.org/10.1016/J.JSAT.2022.108747
U2 - 10.1016/j.jsat.2022.108747
DO - 10.1016/j.jsat.2022.108747
M3 - Article
VL - 138
JO - Journal of Substance Abuse Treatment
JF - Journal of Substance Abuse Treatment
ER -